The average age across of our subjects was under 60 years, and although relatively young is appropriate for preclinical analysis of individuals at high risk for future AD (APOE-e4 homozygotes) whose mean age of onset is typically between the late 60's and mid 70's. The gene discussed is APOE; the disease is Alzheimer disease.